Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has worked diligently but unsuccessfully to create a single therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as a combination treatment in the therapy of multi-drug-resistant HIV have been closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the past few shares of mine. The first CytoDyn article of mine, “CytoDyn: What To Do When It is Too Good to be able to Be True?”, set out all of the following prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan offered such a very promotional picture in the Uptick Newswire job interview which I came away with an inadequate impression of the company.

Irony of irony, my poor viewpoint of the company has grown steadily, however, the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger at the moment still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the treatment and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this expertise as well as connected intellectual property from Progenics to CytoDyn, as well as roughly twenty five million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 zillion) and the very first new drug application endorsement ($5 million), and also royalty payments of five percent of net sales upon commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to get a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many indications and many therapies, it has this single remedy as well as a “broad pipeline of indications” because it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely advantageous therapy of dozens of indications.

Its opening banner on the website of its (below) shows an active business with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple publications and multiple delivering presentations.

Could all this be smoke cigarettes and mirrors? That is a question I’ve been asking myself with the really beginning of the interest of mine in this particular organization. Judging by way of the multiples of a huge number of diverse comments on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m far from alone in this question.

CytoDyn is a traditional battleground, or even some could say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *